TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cumulative death rates from all causes
Endpoint domain: Mortality/survival
Primary endpoint: Minimum plasma concentrations required to inhibit 90% of susceptible micro‐organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cecal intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall ACE tool scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Response (SR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall improvement in health behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in sleep behavior (earlier bedtime)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebrovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nocturnal sleep efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in documentation time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increase in patient care time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Non-emergence of bloody stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: frequency of hospital release at 24 hrs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Blood glucose levels exceeding 10 mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recidivism rate
Endpoint domain: Mortality/survival
Primary endpoint: Post-ERCP pancreatitis (PEP)
Endpoint domain: Adverse events/effects
Primary endpoint: ocular treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Interincisal angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mentolabial angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total fibromyalgia symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean plaque area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality or worsening heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic progression-free survival (PFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time until PSA progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle endurance (bench press repetitions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI activations concordant with language areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient postsurgical language deficits
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of electrical cardioversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentrations of atrial natriuretic peptide (ANP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PTSD improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression improvement (children)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression improvement (parents)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic outcome classification
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ALFI‐MMSE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HUI3 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Omega-3 index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of laryngeal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 3D implant positioning accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DTN time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of CD38+ and HLA-DR+ on CD4/CD8 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain medication usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recovery of detrusor contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rehospitalization percentage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bayley‐II Mental Developmental Index <70 percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of infants with neurodevelopmental impairments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major depression symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation of interferon alfa due to severe depression
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative anastomotic leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Repeat operations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: survival rate at 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Mean SBP after HD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HD terminations
Endpoint domain: Adverse events/effects
Primary endpoint: Success rates of infraclavicular subclavian venous catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 1-year noncardiac mortality
Endpoint domain: Mortality/survival
Primary endpoint: bone fusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident cases of type 2 diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Consent rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness of obtaining informed consent
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain relief (VAS < 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of girls whose parents gave consent for vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of advanced prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Area under the time‐plasma concentration curve (AUC(0‐24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative amplitude of the pupil light reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: saquinavir AUC(0-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering urinary albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in blood glucose after meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NO flow requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: INSP‐NOMeas stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TRACH‐NOMeas fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work performance score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Urinary index score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement rate at maximum frown by live assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression to normoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression to incident diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hip abductor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensitivity of stroke symptom detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of stroke symptom detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3/4 hematopoietic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: objective response rates (CR/PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds for success at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds for success at 26 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment benchmarks achieved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant follow-up time accrued
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Shift from 'severe' to 'moderate' asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adipose tissue release of LPL mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean PD change at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological failure (VF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise-induced sweat production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual field progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cessation of smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smoking location change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post‐intervention knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fatal events
Endpoint domain: Mortality/survival
Primary endpoint: readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: days of associated hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prediction of EGFR expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinically meaningful improvement in AMPS activities of daily living ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: time to subjective clinical fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WPAI scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Efficacy against HPV16/18-related cervical intraepithelial neoplasia Grade 2 or 3, adenocarcinoma in situ, and cervical cancer (CIN 2+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy against HPV6/11/16/18-related CIN 1+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy against cervical 6-month and 12-month persistent infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Graft uptake rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total active motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in lumbar multifidus muscle recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Miss rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor recurrence after liver transplantation
Endpoint domain: Mortality/survival
Primary endpoint: clinical and radiographic cumulative survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Urinary IL-8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean pain score during ESWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of cognitive deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-rating of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of psychosocial communication skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Duration of seizure free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Long-term success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of cariogenic bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence and severity of pain from propofol injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and intensity of withdrawal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of errors on laparoscopic task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective sleepiness score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: overall educational experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ability to interpret endovaginal US images
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: evaluation of residents' skills in interpreting endovaginal US images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing SPT/recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Mean Bishop score increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean interval from catheter withdrawal to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolactin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Folic Acid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Admission time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Frey's syndrome onset
Endpoint domain: Adverse events/effects
Primary endpoint: Facial nerve impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Silane film thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface roughness (Ra and Rq)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommendations for contraceptive methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Concerns about infertility
Endpoint domain: Adverse events/effects
Primary endpoint: Concerns about pain with IUC use
Endpoint domain: Adverse events/effects
Primary endpoint: emergence of suicidal ideation
Endpoint domain: Adverse events/effects
Primary endpoint: tolerability of valbenazine
Endpoint domain: Adverse events/effects
Primary endpoint: psychiatric stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in average lumen area (LA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percent atheroma volume (PAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: predose FEV1 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: propofol usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procedure-related pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repigmentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SRI-4 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ideal CHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High sensitivity troponin T level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Forced expiratory volume in the first second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: neuropathic-type pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pain on normal daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical Global Impression improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate (CDRS-R ≤ 28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flare intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Photodamage Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: visiometer R values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin irritation and sensitization assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Blood glucose levels above normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in urinary cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in urinary 5-HIAA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lessening of anxiety status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Categorized combination of the Barthel and Rankin scales assessed at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Substance use trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total DSR score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Programme costs per child
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: BMI SDS outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elbow and wrist function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative diuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: FM impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functionality domains (flexibility, balance, coordination, endurance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response inhibition as measured by Conners Continuous Performance Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: V[Combining Dot Above]O2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of macrolides in chronic rhinosinusitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: penetration of irrigant into lateral canals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in astigmatism magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average LAD (degrees)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average CAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depressive symptoms (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Protein carbonyl content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SH groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipoatrophy prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mtDNA in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mtDNA content in subcutaneous adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: willingness to accept risk of urinary incontinence or impotence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mini-mental state examination score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Addenbrooke's cognitive examination scores in attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Addenbrooke's cognitive examination scores in memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: knowledge about illness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning